← Leaderboards
Deepa G Manwani
Mount Sinai School Of Medicine Of Nyu
$2,499,850
Attributed
$2,499,850
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $400K · FY2009–19$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
FDA$1,800,000 · 2
NIH$699,850 · 2
By mechanism
R01$1,800,000 · 2
K08$631,375 · 1
OT2$68,475 · 1
Top collaborators
No co-investigators on record.
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Paul S Frenette$23,833,846
- Lewis Silverman$10,485,930
- Rona S Weinberg$12,948,774
- Ali G Gharavi$45,808,576
- Edward A Fisher$34,926,928
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapySickle Cell AnemiaErythrocytesGene RearrangementGenetic ManipulationErythropoiesisGlobinEmbryonic Stem CellTranscription FactorTransfectionTissue /Cell CultureGenetically Modified AnimalsLaboratory MouseDisease MarkerCurative TreatmentsBiomarker ValidationClinical MarkersCandidate ValidationBiological MarkersAreaGamunexCandidate MarkerFoundationsFlow Cytometry
Grant awards (12)
Analytical and/or Clinical Validation of Candidate Biomarkers for Curative Therapies in Sickle Cell Disease$68,475
OT2 · FY2019 · HL · contact PI
Phase 2 Trial of Gamunex ( Intravenous Gammaglobulin) for Sickle Cell Acute Pain$286,059
R01 · FY2018 · FD · contact PI
Phase 2 Trial of Gamunex ( Intravenous Gammaglobulin) for Sickle Cell Acute Pain$113,941
R01 · FY2018 · FD · contact PI
Phase 2 Trial of Gamunex ( Intravenous Gammaglobulin) for Sickle Cell Acute Pain$400,000
R01 · FY2017 · FD · contact PI
Phase 2 Trial of Gamunex ( Intravenous Gammaglobulin) for Sickle Cell Acute Pain$400,000
R01 · FY2016 · FD · contact PI
Phase 2 Trial of Gamunex ( Intravenous Gammaglobulin) for Sickle Cell Acute Pain$400,000
R01 · FY2015 · FD · contact PI
Phase 1-2 trial of Gamunex (intravenous gammaglobulin) for Sickle Cell Acute Pain$200,000
R01 · FY2009 · FD · contact PI
USE OF MODIFIED EKLF FOR GAMMA GLOBIN AUGMENTATION$128,331
K08 · FY2004 · DK
USE OF MODIFIED EKLF FOR GAMMA GLOBIN AUGMENTATION$128,331
K08 · FY2003 · DK
USE OF MODIFIED EKLF FOR GAMMA GLOBIN AUGMENTATION$129,411
K08 · FY2002 · DK
USE OF MODIFIED EKLF FOR GAMMA GLOBIN AUGMENTATION$122,651
K08 · FY2001 · DK
USE OF MODIFIED EKLF FOR GAMMA GLOBIN AUGMENTATION$122,651
K08 · FY2000 · DK